cyrilzakka/clinical-trials huggingface dataset:
Muscle Property, Alignment and Joint Loading in People With Knee Osteoarthritis

Knee osteoarthritis (KOA) is a common chronic painful musculoskeletal condition among older adults. It poses great challenge to the health care system due to its inability to be cured. Understanding factors associated with disease progression in KOA should assist the development of novel prevention/rehabilitation strategies. This study investigate factors including muscle properties, lower limb alignment and joint loading in patients with knee osteoarthritis before and after a six-week exercise program.


Eligibility Criteria:
Inclusion Criteria:

1. Age between 50-80
2. having radiographic tibiofemoral joint OA in the medial compartment defined as Kellgren and Lawrence grade = 2 to 3
3. having medial knee pain on most days of the month
4. having a minimum average pain score of 2 on an 11-point numerical rating scale in the past week while walking

Exclusion Criteria:

1. having lateral tibiofemoral compartment osteophytes greater than the medial side.
2. having undergone intra-articular corticosteroid injection or knee surgery to either knee within the past 3 months
3. having a systemic arthritic condition (e.g., rheumatoid arthritis)
4. having a knee joint replacement or high tibial osteotomy in the past
5. having any other muscular, joint or neurological condition influencing lower limb function
6. unable to walk unaided
7. having low back, hip, ankle or foot pain \> 3 on numerical rating scale
8. having a body mass index (BMI) \>36 kg/ m2
VR vs. Conventional Cycling Exercise for Geriatric Inpatient Physical Activation

The aim of this study is to investigate whether virtual reality assisted stationary cycling exercise results in more physical activity than conventional unsupervised stationary cycling exercise. Physical activity levels are reported for both exercise duration and volume and non-exercise activity.


Eligibility Criteria:
Inclusion Criteria:

* Admitted to geriatric ward at Bispebjerg Hospital with an minimum of 3 days (anticipated) left of stay.
* Volunteering

Exclusion Criteria:

* Unable to be easily mobilized by training staff.
* Unable to perform the stationary cycling exercise modality.
* Lack of Danish speaking and reading skills.
* Lack of senses (blind, deff pr heavily hearing impaired).
* Suffering from delirium, vertigo or dementia beyond a moderate degree.
* Judged medically contraindicated by therapeutic, medical or care staff
Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves

The purpose of this study is to evaluate and compare the clinical outcomes after implantation of the porous plate (polyethylene) (Model M4) Ahmed Glaucoma Valve with the silicone plate Ahmed Glaucoma Valve (Model FP7) in participants with refractory glaucoma.

The purpose of this study is to evaluate and compare the clinical outcomes after implantation of the porous plate (polyethylene) (Model M4) Ahmed Glaucoma Valve with the silicone plate Ahmed Glaucoma Valve (Model FP7) in participants with refractory glaucoma. Participation will last for 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Male or female of any race ≥ 18 years and ≤ 80 years of age.
* Diagnosis of intractable glaucoma in the study eye, with the exception of silicone oil endotamponade induced glaucoma, which has not responded to conventional medical and surgical therapy.
* Elevated intraocular pressure \> 21 mmHg in the study eye. Two consecutive measurements using Goldmann Applanation Tonometry will be obtained and the mean of those two measurements will be considered the subject's baseline intraocular pressure.
* Subject is a candidate for surgery in the study eye with a glaucoma drainage device.
* Subject is willing and able to sign the informed consent.

Exclusion Criteria:

* Diagnosis of silicone oil endotamponade induced glaucoma in the study eye.
* History of prior drainage implant surgery in the study eye.
* History of cyclophotocoagulation of the study eye.
* Pregnancy.
* Prisoner.
STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue

Decentralized, randomized hybrid type 2 (effectiveness/implementation) controlled trial comparing the effectiveness of three different digital aid modalities programs in reducing the perceived burden of CRF in cancer patients while also gathering data on the implementation strategy.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years and older.
* Having a clinical diagnosis of cancer including patients on active treatment or cancer survivors.
* Self-reporting moderate to severe CRF for at least one week (worst level of fatigue ≥ 4 on a 10-point numerical rating scale, retained in international guidelines as an optimal cutoff for identifying clinically significant CRF).
* Being able to read and understand French.
* Having access to a smartphone.
* Patients must be affiliated to a social security system or beneficiary of the same.

Exclusion Criteria:

* Suffering from current psychiatric disorder or cognitive disorder that would interfere with the ability to consent or participate.
* Currently engaging in cognitive-behavioral therapy.
* Currently engaging in another non-drug (behavioral) clinical trial.
* Suffering from physical related reversible and treatable causes of fatigue (anemia, electrolytes unbalance, infections, renal dysfunction, active metastases causing fatigue, hormonal unbalances (hypothyroidism, adrenal insufficiency, etc.) - according to physician's judgement at the moment of inclusion.
Comparison of the Effectiveness of the USG and CBCT Combined With Intraoral Scanning Determing the Gingival Phenotype in the Healthy Periodontium

Compare two diagnostic methods: UGTM and CBCT/CAD/PDIP in determing the gingival phenotype in group of 30 periodontally healthy patients. Both methods were useful to establishing the gingival phenotype, however, ultrasonic method was more precisely for measurement of gingival thickness. There was positive correlation between the mean values of SGT and WKT and this indicates the need to measure these parameters in order to determine gingival phenotype.

Gingival phenotype (GP) should be determine in each dento-gingival unit as a 3D volume of gingiva with the following parameters: width of keratinized tissue (WKT) and gingival thickness (GT). The phenotype determination is extremely important during many dental procedures, such as in dental surgery, orthodontics, prosthetics or implantology because it allows to dental treatment planning and reduce the risk of complications. Previous methods of determining the gingival phenotype were based on the shape of the crowns of the upper incisors and transparency of the free gingiva. These methods are non-invasive, but innacurate. The gingival phenotype may be determined more precisely by using biometry of WKT and GT. There are several possible methods to measure the thickness of the gingiva, such as bone sounding, cone beam comuted tomography (CBCT) measurement or parallel profile radiographs, CBCT/CAD (CBCT and computer-aided design) and ultrasound method. The ultrasonic gingival tissue measurement (UGTM) method is non-invasive, removes the need for anesthesia, which may increases the volume of tissues, but requires the experience of the researcher. However, it is considered as effective and reproducible method of the measurement soft tissue thickness. CBCT/CAD/PDIP (CBCT/CAD and prosthetic-driven implant planning) method also can be used to establishing the gingival phenotype.

Measurements of WKT are most often carried out using a periodontal probe calibrated every 1mm. In each case, a necessary condition for the proper examination of the patient and determination of GP is healthy periodontium.

Eligibility Criteria:
Inclusion Criteria:

* lack of general diseases
* good oral hygiene
* healthy periodontium - API ratio\&lt;15%, BOP\&lt;10%
* no loss of clinical attachment in the examined areas (CAL=0)
* no use of drugs
* no addictions, especially cigarette smoking
* no use of mobile prosthetic restorations and orthodontic appliances
* no contraindications for X-ray examinations

Exclusion Criteria:

* general diseases
* poor oral hygiene
* non healthy periodontium - API ratio\&gt;15%, BOP\&gt;10%
* loss of clinical attachment in the examined areas (CAL\&gt;1)
* use of drugs that could influence the structure of the periodontal tissues
* addictions, especially nicotinism
* use of mobile prosthetic restorations and orthodontic appliances
* contraindications for X-ray examinations
Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus

Recurrence, Complications, Work-off date, Healing time and Patients Willingness in Karydakis Technique for Treatment of Sacrococcygeal Pilonidal Sinus versus Healing by Secondary Intention (EHSI) Technique in Imam Khomeini Hospital from 2008 to 2011


Eligibility Criteria:
Inclusion Criteria:

all types of pilonidal sinus or cyst

Exclusion Criteria:

no exclusion criteria
Mask Adhesive Institutional Study

To reduce interface leak and aerosol spread, Philips has developed an accessory to non-invasive ventilation(NIV) masks to be used with the Philips AF531 and the PerformaTrak mask on respiratory failure patients. For the purposes of capturing initial mask leak and safety data, this trial will enroll patients treated with NIV in an institutional setting (i.e., sleep lab).

The Mask Adhesive will serve as an accessory to the AF531/PerformaTrak masks with the intention to reduce patient leak while a patient is receiving therapy. This accessory is a double-sided adhesive; with one side applied directly to the patient's skin and the other side connected to the mask cushion. Each adhesive is only to be applied to a patient once. The AF531/Performatrak mask can be removed from the adhesive and then re-applied, as necessary. For example, if the patient needs to remove the mask to eat or take medicine, the mask is removed from the patient and the adhesive will stay on the patient's face

Eligibility Criteria:
Inclusion Criteria:

* Adults patients age 18 to 85 (inclusive)
* Adult patients treated with NIV
* Able to read, write, and speak English
* Able to provide written informed consent
* Willing to have facial hair removed for adhesive placement (if required)

Exclusion Criteria:

* Pre-existing allergy to tape or adhesive;
* Blisters, open skin or pre-existing skin condition that may impact the ability to support removal of the mask adhesive without tearing the skin
* pregnant (for females of childbearing age);
* Individuals sentenced to such an institution under a criminal or civil statute,
* Individuals detained in other facilities by virtue of statutes or commitment procedures which provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial, or sentencing
The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases

Background:

-This protocol is concerned with the acquisition of blood, skin, or mucosal samples from healthy volunteers or patients with selected skin diseases to support the basic science and clinical research activities of the Dermatology Branch and other intramural Laboratories and Branches at the NIH Clinical Research Center.

Objectives:

(Primary)

-To allow collection of blood, skin, or mucosal samples from healthy volunteers or patients with selected skin or systemic diseases as needed to support the research activities of our Branch and other Laboratories and Branches.

Eligibility:

* Healthy individuals (including employees and other patients) and patients with selected skin or other diseases, including individuals of both genders and all racial/ethnic groups.
* Patient volunteers must be willing to undergo blood drawing and/or skin/mucosal biopsies.

Design:

-This is dependent upon the particular investigation for which these samples are needed.

Background:

-This protocol is concerned with the acquisition of blood, skin, or mucosal samples from healthy volunteers or patients with selected skin diseases to support the basic science and clinical research activities of the Dermatology Branch and other intramural Laboratories and Branches at the NIH Clinical Research Center.

Objectives:

(Primary)

-To allow collection of blood, skin, or mucosal samples from healthy volunteers or patients with selected skin or systemic diseases as needed to support the research activities of our Branch and other Laboratories and Branches.

Eligibility:

* Healthy individuals (including employees and other patients) and patients with selected skin or other diseases, including individuals of both genders and all racial/ethnic groups.
* Patient volunteers must be willing to undergo blood drawing and/or skin/mucosal samples/monitoring.

Design:

-This is dependent upon the particular investigation for which these samples are needed.

Eligibility Criteria:
* INCLUSION CRITERIA:

Healthy individuals (including employees and other patients), and patients with selected skin or other diseases, including individuals of both genders and all racial/ethnic groups.

Patient volunteers must be willing to undergo blood drawing and/or skin/mucosal sampling/monitoring to include non-invasive skin samples.

EXCLUSION CRITERIA:

Strong family history and/or evidence of keloid formation following surgery or trauma.

Children under the age of 18 years.

Pregnant women
Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function

To investigate the effect of antioxidants (Vitamin C) on the vascular damage induced hypoglycemia in patients with type 1 diabetes. The vascular injury was evaluated in the same way as main objective. Checking the existence of a peripheral response to the action of GLP-1 due to oxidative stress.

Eligibility Criteria:
Inclusion Criteria:

* Informed and signed consent obtained before any trial-related activity . ( Trial-related activities are those procedures that were not performed during routine medical examination of the patient) .
* Diagnosis of type 1 diabetes.
* Patients who do not have autonomic dysfunction , defined by ( 1).
* Patients not showing episodes of hypoglycemia unawareness based on the methods of Gold et al (2) .
* Patients without microvascular complications of diabetes.
* Patients without macrovascular complications of diabetes.
* Patients treated with multiple daily injections of insulin.
* No smoking .
* They should have a complete blood count, lipid profile, liver profile , renal profile and plasma electrolyte levels within normal values .
* No subject must have a history of hypertension or taking medication for high blood pressure .
* No subject should be taking medications known to affect the neuroendocrine responses to hypoglycemia or anti inflammatory

Exclusion Criteria:

* Known or suspected hypersensitivity to study some related products.
* Fertile women, lactating or pregnant, intend to become pregnant or who are not using adequate contraception, or men who have sexually active and are not sterilized surgically, those whose partners are not using a method adequate contraception.
* Clinical diagnosis of Type 2 Diabetes.
Analysis of Risk Factors of Postoperative Pulmonary Infection in Patients With Esophageal Cancer

The goal of this observational study is to learn about in describe participant population. The main questions it aims to answer are:

* What are the risk factors of postoperative pulmonary infection in patients with esophageal cancer？
* Whether we could establish a clinical prediction model to provide basis for early clinical intervention or not? Participants will describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items. If there is a comparison group: Researchers will compare insert groups to see if insert effects.

Data were collected from the electronic medical records of Xijing Hospital. Each record is entered by two team members working simultaneously to ensure data accuracy.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of esophageal cancer;
* Radical resection of tumor for the first time;
* No distant metastasis was observed in preoperative examination

Exclusion Criteria:

* Patients with preoperative pulmonary infection or symptoms of pulmonary infection;
* Patients with tracheal intubation assisted ventilation before surgery;
* Patients with preoperative lung imaging changes or abnormal white blood cells in blood routine;
* Patients undergoing emergency surgery;
* Patients with other cancers;
* Patients with incomplete clinical data.
Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial

Weight loss surgery is the most effective weight loss treatment available, but the direct effect on chronic kidney disease is less widely understood. Early research shows some improvement in kidney function may occur and candidacy for kidney transplantation can be improved with weight loss following surgery. To date, no randomised controlled trial has been performed to examine the effect of weight loss surgery on the progression of chronic kidney disease.

This randomised trial will allocate patients to either lifestyle modification with diet, exercise and pharmacotherapy, or weight loss surgery to remove two thirds of the stomach using the laparoscopic sleeve gastrectomy procedure. This study aims to evaluate weight loss surgery vs lifestyle modification in patients with chronic kidney disease with estimated kidney function of 20-60% and morbid obesity (BMI 35-45) in terms of kidney function, cardiovascular disease risk factors and all-cause mortality.


Eligibility Criteria:
Inclusion Criteria:

* Stages 3-4 CKD patients (GFR 20-60 mL/min)
* Male or female
* BMI 35-45 kg/m2
* Aged \>18 years
* Previously attempted weight loss
* Fit or anesthesia and surgery
* Written informed consent

Exclusion Criteria:

* Pregnancy
* History of chronic liver disease
* Previous gastric surgery or large hiatus hernia
* Previous bariatric surgery
* Psychiatric illness, including anxiety, mood and untreated eating disorders
* Malnutrition (assessed by subjective global assessment)
* Infection or course of antibiotics within the last month
* Unwilling to consider surgical treatment
* Previous kidney transplant
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism

40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month. Blood samples will be collected before the study and at weeks 1 and 4 and also, two weeks after finishing the diet. Main study focuses are LDL aggregation susceptibility, lipid composition and proteoglycan binding affinity. In addition, important plasma lipid metabolism enzymes and lipid mediated resolvins are measured as well as several baseline characteristics.

Four grams of daily E-EPA was found to significantly decrease atherosclerotic cardiovascular diseases in the REDUCE-IT study. In the upcoming study the effect of E-EPA to low-density lipoprotein (LDL) aggregation susceptibility is measured using dynamic light scattering technique to continuously measure particles size while inducing aggregation. LDL Lipid composition is analyzed using electrospray mass spectrometer optimized for lipid measurements. Previously is reported that the aggregation susceptibility is affected by the lipid composition which is modifiable (Ruuth et. al. Eur.H.Journal 2018). Common disease factors such as total cholesterol, LDL, HDL, triglyserides, ApoB-100, ApoA-I, Lp(a) and different modified LDL levels are measured. Also, activities of lipid metabolism enzymes like PON-1, LCAT, CETP, PLTP and lipid mediated resolvins are looked into. Objective is to identify changes and possible pathways that are altered by the increase of E-EPA and to use the data to possibly explain the health benefits of EPA.

Eligibility Criteria:
Inclusion Criteria:

* Healthy normolipidemic

Exclusion Criteria:

* Prescription of blood thinner medicine
* Circulating Low-density lipoprotein \> 5mmol/l, Triglycerides \>3mmol/l
* Chronic use of pain medication
* Fish allergy
* Pregnancy
* Breastfeeding
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.

This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular edema and prior treatment with ≥ 2 intravitreal anti-VEGF injections.

Eligibility Criteria:
Inclusion Criteria:

* Presence of NPDR or PDR as confirmed by fluorescein angiography
* Prior treatment with \>= 2 intravitreal anti-VEGF injections but no treatment in last 4 weeks
* \< 0.1 LogOCT decrease in macular edema on high resolution OCT between initial visit and following treatment with \>= 2 intravitreal anti-VEGF injections
* Age 18 years or older
* ETDRS Visual acuity between 3 and 78 letters (approximate Snellen equivalent of 20/25 to 20/800)
* Ability to provide written informed consent
* Capable of complying with study protocol.

Exclusion Criteria:

* Intraocular injection of steroid medication within prior 3 months
* Evidence of significant geographic atrophy on fluorescein angiography in the opinion of the treating physician
* Concurrent ocular disease (wet AMD, significant ERM, etc) that would limit visual acuity in the opinion of the treating physician
* Prior vitrectomy surgery
* Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to day 1.
* Known history of IOP elevation in response to steroid treatment in either eye that resulted in any of the following: a) = 10 mm Hg increase in IOP in response to steroid injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma medications to keep IOP below 21 mm Hg.
* Patients who are pregnant.
* Unwilling or unable to follow or comply with all study related procedures